26 September 2025

Futura Medical plc

("Futura" or the "Company")

Notice of Results & Investor Presentation

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will release its interim results for the six months ended 30 June 2025 on Tuesday 30 September.

Management will be hosting a webinar relating to the results via the Investor Meet Company platform on 30 September 2025, at 09.30am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST the day before, or at any time during the live presentation.

Investors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor. Investors who already follow Futura on the Investor Meet Company platform will automatically be invited.

Contacts:

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon^® and new products in development WSD4000 and Eroxon^® Intense. The Company's core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. Erectile dysfunction (ED) impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of impaired sexual response and function, yet only one in four women seek professional help and remain chronically underserved.

Eroxon^®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection within ten minutes, addresses significant unmet needs in the ED market. Eroxon^® has been nominated for a number of healthcare industry awards and to date has won two.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the USA, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.